HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy...
Hence then, the article about akeso announces the publication of its phase iii clinical trial results for ivonescimab in head to head comparison with pembrolizumab in the lancet was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet )
Also on site :
- Readers push back on ChatGPT use in Massachusetts executive branch
- Yankees& 039; Giancarlo Stanton Reveals How Injury Impacts Everyday Life
- My Therapist Will Be Hearing About ‘Smiling Friends’ Ending